<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4635">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046589</url>
  </required_header>
  <id_info>
    <org_study_id>DP13C101</org_study_id>
    <nct_id>NCT03046589</nct_id>
  </id_info>
  <brief_title>DP13 SAD &amp; MAD in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of DP13 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damian Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation for Therapeutic Research, Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Damian Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        1. To determine the safety and tolerability of single and multiple oral doses of DP13 in
           healthy male subjects

        2. To assess the pharmacodynamics of single and multiple ascending oral doses as well as
           dosing regimen of DP13 on suppression of serum aldosterone in healthy male subjects

      Secondary Objectives:

        1. To determine the single and multiple oral dose pharmacokinetics of DP13 in healthy male
           subjects

        2. To determine the dose-dependent pharmacodynamic selectivity of DP13 in healthy male
           subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability (Clinical signs and symptoms incl ECG, vital signs, electrolytes)</measure>
    <time_frame>Up to 2 weeks after dosing</time_frame>
    <description>Clinical signs and symptoms incl ECG, vital signs, electrolytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aldosterone suppression</measure>
    <time_frame>Up to 48 hours after dosing</time_frame>
    <description>Serum aldosterone concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma DP13 concentration)</measure>
    <time_frame>up to 48 hours after dosing</time_frame>
    <description>Plasma DP13 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic selectivity (Plasma hormone concentrations)</measure>
    <time_frame>Up to 48 hours after dosing</time_frame>
    <description>Plasma hormone concentrations</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Safety and Tolerability</condition>
  <arm_group>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 capsules (dose level 1 ) and placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 capsules (dose level 2) and placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 capsules (dose level 3) and placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 capsules (dose level 4) and placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 capsules (dose level 5) and placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 capsules (dose level 6) and placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP13</intervention_name>
    <description>dose escalation</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <arm_group_label>Treatment Period 5</arm_group_label>
    <arm_group_label>Treatment Period 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <arm_group_label>Treatment Period 5</arm_group_label>
    <arm_group_label>Treatment Period 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. BMI between 18.0 and 30.0 kg/m2, inclusive

          2. body weight between 60 and 95 kg, inclusive

          3. good health as determined by medical history, physical examination, vital signs
             assessment, 12-lead ECG, clinical laboratory evaluations

          4. normal stress response

          5. sodium value within the normal laboratory reference range

          6. potassium value within the normal laboratory reference range

          7. written informed consent

        Exclusion Criteria:

          1. unwilling to consent or whose partner is unwilling to consent to use a barrier method
             of contraception

          2. blood donation within 3 months prior to screening or plasma donation within 7 days
             prior to screening or platelet donation within 6 weeks prior to screening

          3. consumption of more than 28 units of alcohol per week or significant history of
             alcoholism or drug/chemical abuse within the last 12 months prior to screening

          4. use of tobacco or nicotine-containing products within 3 months

          5. use of any of the following within 14 days of first dose: non-prescribed systemic or
             topical medication; any herbal remedy; any vitamin supplement; any mineral supplement

          6. receipt of any medications, including St John's Wort, known to chronically alter drug
             absorption or elimination processes

          7. receipt or intent to receive: any prescribed systemic or topical medication within 14
             days of first dose administration

          8. an abnormality in heart rate, blood pressure, temperature or respiration rate at
             screening and prior to first dose that in the opinion of the investigator increases
             the risk of participating in the study

          9. a positive urine drugs of abuse screen

         10. an abnormality in the 12-lead ECG at screening and prior to first dose that in the
             opinion of the investigator increases the risk of participating in the study

         11. a medical history of clinically significant ECG abnormalities or a family history of
             a prolonged QT-interval syndrome

         12. participation in another clinical study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Brooks, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa M Charles</last_name>
    <phone>+ 44 113 301 3727</phone>
    <email>lisa.charles@covance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa M. Charles</last_name>
      <phone>+ 44 113 301 3727</phone>
      <email>lisa.charles@covance.com</email>
    </contact>
    <investigator>
      <last_name>Ashley Brooks, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 24, 2017</lastchanged_date>
  <firstreceived_date>February 5, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
